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    Central retinal vein occlusion (CRVO) is a common retinal vascular disorder which affect 
the patient visual ability. Visual prognosis depends on the type of retinal vein occlusion, that can be ischemic or non-ichemic, its 
severity, degree of retinal ischemia or macular edema and development of complications. The two most frequent complications of 
CRVO are persistent macular edema and neovascularization. One of the best and effective treatment for macular edema and 
neovascularisation seems to be intra vitreal anti-VEGF. Case report: We report 3 cases of CRVO with macular edema, treated with 
3 intavitreal aflibercept (EYLEA) in 3 months. The Visual acuity (VA) improved on all 3 cases after each injection. This article 
aims to review the effect of anti-VEGF drugs in macular edema and improving vision in patients with CRVO.  
 
Introduction 
Retinal vein occlusion (RVO) is a common cause of vision loss in older individuals, and the 
second most common retinal vascular disease after diabetic retinopathy. CRVO is divided into the 
categories of perfused (nonischemic) and nonperfused (ischemic), each of which has implications 
for prognosis and treatment. On initial presentation, it may be difficult to classify a given patient 
into either category, since CRVO may change with time. Nonischemic CRVO is the milder form 
of the disease. It may present with good vision, few retinal hemorrhages and cotton-wool spots, no 
relative afferent pupillary defect, and good perfusion to the retina (figure nr. 1).   
 
Figure 1. 
Nonischemic CRVO may resolve fully with good visual outcome or may progress to the 
ischemic type. Ischemic CRVO is the severe form of the disease. CRVO may present initially as 
the ischemic type, or it may progress from nonischemic. Usually, ischemic CRVO presents with 
severe visual loss, extensive retinal hemorrhages and cotton-wool spots, presence of relative 
afferent pupillary defect, poor perfusion to retina, and presence of severe electroretinographic 
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changes (Figure nr. 2). In addition, patients may end up with neovascular glaucoma and a painful 
blind eye. 
 
Figure 2. 
The exact pathogenesis of the thrombotic occlusion of the central retinal vein is not known. 
Arteriosclerotic changes in the central retinal artery transform the artery into a rigid structure and 
impinge upon the pliable central retinal vein, causing hemodynamic disturbances, endothelial 
damage, and thrombus formation. Thrombotic occlusion of the central retinal vein can occur as a 
result of various pathologic insults, including compression of the vein (mechanical pressure due to 
structural changes in lamina cribrosa, eg, glaucomatous cupping, inflammatory swelling in optic 
nerve, orbital disorders); hemodynamic disturbances (associated with hyperdynamic or sluggish 
circulation); vessel wall changes (eg, vasculitis); and changes in the blood (eg, deficiency of 
thrombolytic factors, increase in clotting factors). It has been postulated that ischemic damage to 
the retina stimulates increased production of vascular endothelial growth factor (VEGF) in the 
vitreous cavity. Increased levels of VEGF stimulate neovascularization of the posterior and 
anterior segment (responsible for secondary complications due to CRVO). Also, it has been shown 
that VEGF causes capillary leakage leading to macular edema (which is the leading cause of 
visual loss in both ischemic CRVO and nonischemic CRVO). Approximately 81% of the patients 
with CRVO are of the non-ischemic, and only 19% are of the ischemic type. 
Risk factors in CRVO: 
Hypertension 
Diabetes mellitus 
Cardiovascular disorders 
Bleeding or clotting disorders,polycythemia vera, lymphoma, leukemia 
Alcohol consumption 
Amount of physical activity 
Vasculitis, Syphilis, sarcoidosis 
Autoimmune disorders,Systemic lupus erythematosus 
Use of oral contraceptives 
Closed-head trauma 
Primary open-angle glaucoma or angle-closure glaucoma 
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Ocular symptoms at initial presentation are as follows: 
Asymptomatic 
Decreased vision 
 
Visual loss can be sudden or gradual, over a period of days to weeks. Visual loss ranges from 
mild to severe. Patients can present with transient obscurations of vision initially, later progressing 
to constant visual loss. 
 
Photophobia 
Painful blind eye 
Redness of eyes 
 
Ocular symptoms in later stages are as follows: 
 
Decrease of vision 
Pain in the eye 
Discomfort 
Redness 
Watering 
 
 
Clinical Presentation & Diagnosis 
CRVO is classically characterized by optic disc swelling, increased venous dilatation and 
tortuosity, widespread deep and superficial hemorrhages, cotton wool spots, retinal edema, and 
capillary nonperfusion. A number of clinical and fluorescein angiographic features can help to 
distinguish between ischemic and non-ischemic CRVO. Ischemic CRVO is more severe, and is 
associated with profound visual loss (visual acuity worse than 20/200), severe clinical signs and a 
marked afferent pupillary defect. However, during the early acute phase of CRVO, such 
differentiation can be less distinct and a combination of functional tests may be required to 
achieve a more accurate diagnosis to aid the management plan. Iris neovascularization develops in 
approximately 35% of eyes with a risk of neovascular glaucoma, unless they are treated 
vigorously with panretinal photocoagulation. As a general rule, this risk of iris neovascularization 
is higher if the area of retinal ischemia (retinal nonperfusion as determined by fluorescein 
angiogram) is >10 disc diameters.  
 
Patients with central retinal vein occlusion (CRVO) should undergo a complete eye 
examination, including visual acuity, pupillary reactions, slit lamp examination of the anterior and 
posterior segments, undilated examination of the iris, gonioscopy, fundus examination with 
indirect ophthalmoscope, and fundus contact lens. 
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Laboratory test (all patients) 
Blood pressure, Erythrocyte sedimentation rate (ESR), Full blood count (FBC), Random blood 
glucose, Random total and HDL cholesterol, Plasma protein electrophoresis (dysproteinemias 
such as multiple mieloma), Urea, electrolytes and creatinine (renal disease in association with 
hypertension), Thyroid function tests (associated with dyslipidemia), ECG (left ventricular 
hypertrophy secondary to hypertension). 
Treatment  
No known effective medical treatment is available for either the prevention of or the treatment 
of central retinal vein occlusion (CRVO). Identifying and treating any systemic medical problems 
to reduce further complications is important.  
Advocated treatments are as follows: 
Aspirin 
Anti-inflammatory agents 
Isovolemic hemodilution 
Plasmapheresis 
Systemic anticoagulation with warfarin, heparin, and alteplase 
Fibrinolytic agents 
Systemic corticosteroids 
Local anticoagulation with intravitreal injection of alteplase 
Intravitreal injection of ranibizumab 
Intravitreal injection of aflibercept 
Intravitreal injection of triamcinolone 
Intravitreal injection of bevacizumab 
Dexamethasone intravitreal implant 
 
Case report 1 
B.M is a 64 year old man who presented at eye clinic, UHC‖Mother Theresa‖ Tirana,  3 days 
after having blurred vision on his left eye. He had a history of hypertension for 8 years. After the 
examination it was noted a CRVO with severe macular edema on left eye with BCVA 2/20. 
(figure nr. 3)  
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Figure 3. 
 
Immediately after the examination and full laboratory tests, we performed an 0.05ml 
intraviteal injection of aflibercept 40mg/ml  (EYLEA), followed by 2 more injection for the next 2 
months. During this period we advised him to use timolol maleate 0.5% drops and  acetazolamide 
tab 250mg/p.os.  After 3 months we noticed a reduction of macular edema and a BCVA 8/20 
(figure nr. 4).   
 
 
 
 
 
 
Figure 4. 
Case report 2  
Sh.V  is a 58 years old woman with a 10 years history of Diabet Mellitus and hypertension. 
She presented at the eye clinic 2 weeks after she noticed a reduction on her visus on the left  eye. 
After the examination with OCT and fluorescein angiography we noticed a ischemic CRVO with 
severe macular edema and VA 1/20, and immediately performed a intravitreal injection of 
aflibercept 40mg/ml. (figure nr. 5). This injection was followed by 3 other injections every 4 
weeks. 
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Figure 5. 
 
After 5 months  we noticed a reduction of macular edema from 905 m to 525 m on OCT and 
an improvement on patient visual acuity at about 4/20.  (figure nr. 6)  
 
 
Figure 6. 
Case report 3  
B.B is a 51  year old man with history of hypercholesterolemia and hypertension. He presented 
at our clinic with a blurred vision on his right eye since the night before. After the examination it 
was noted an ischemic CRVO with a severe macular edema at about 880 m. We performed an 
intravitreal injection of aflibervept 40mg/ml wich was followed by 4 other injection in the next 6 
months. In figure nr 7 we can notice the diference on macular edema after 5 injection of 
aflibercept. Huge reduction of macular edema was noticed and the patient gained a visus from 
2/20 to 10/20.  
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Figure 7. 
Discussion  
The increase in VEGF, is triggered by hypoxia in pathological conditions. Increased plasma 
levels of VEGF were first found in diabetic patients, and were highest in preproliferative and 
proliferative retinopathy. Human eyes with CRVO showed evidence of intraretinal upregulated 
expression of VEGF mRNA. Indeed, raised levels of VEGF have been reported in both the 
aqueous and vitreous fluid of patients with ischemic CRVO, and are responsible for the increase in 
vascular permeability that leads to macular edema. Aqueous and vitreous levels of VEGF were 
significantly correlated with the severity of ME. Delivering anti-VEGF antibody into the eye 
therefore, in theory, should help in the treatment of CRVO-ME, as has been shown in diabetic 
ME. Intravitreal aflibercept injections have resulted in a substantial decrease in VEGF under 
physiologic levels and have remained low with the loading doses of three consecutive monthly 
retreatments. 
The Ophthalmic Technology Assessment Committee Retina/Vitreous panel of the American 
Academy of Ophthalmology evaluated available literature regarding efficacy of available 
pharmacotherapies in the treatment of macular edema due to CRVO. The panel reported that 
intravitreal anti-VEGF therapy is safe and effective over 2 years for macular edema and that 
delayed treatment is associated with worse visual outcomes. 
Two parallel trials, the COPERNICUS and GALILEO studies, evaluated the efficacy and 
safety of intravitreal aflibercept injection for the treatment of macular edema secondary to CRVO. 
Aflibercept injection demonstrated a statistically significant difference in the proportion of 
patients who gained 15 or more letters from baseline at week 24 compared with placebo in each 
study. The visual and anatomic improvements were diminished after continued PRN dosing, with 
a reduced monitoring frequency from weeks 52 to 100. 
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Conclusion  
The exact pathogenesis of the CRVO is not known, and various medical modalities of 
treatment have been advocated by multiple authors with varying success in preventing 
complications and in preserving vision. So no known effective medical treatment is available for 
either the prevention of or the treatment of central retinal vein occlusion (CRVO). Anyway 
macular edema is a  treatable cause of decreased visual acuity in patients with CRVO. Various 
treatment modalities have been used, with significant progress in stabilizing or improving visual 
acuity. One of the best and safest way to do that is by using intravitreal anti-VEGF. We advice to 
perform 3 intravitreal injection of anti-VEGF every month, followed by injection every 2 month 
after that, depending on the macular edema of each case.  
The studies and experience demonstrate that long-term anti-VEGF therapy and more frequent 
monitoring is necessary to control macular edema in many patients with CRVO, likely because the 
continued ischemia leads to continued  VEGF production.  
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